High-throughput nano-biofilm microarray for antifungal drug discovery

mBio

Volumn 4, Issue 4, 2013, Pages

  Srinivasan, Anand ^a,b   Leung, Kai P ^c   Lopez Ribot, Jose L ^b   Ramasubramanian, Anand K ^a,b  

^a The University of Texas at San Antonio   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ALLYLAMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BIFONAZOLE; CASPOFUNGIN; CITRININ; CYCLOSPORIN; ETHOXYQUIN; ETOPOSIDE; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; HALOPROGIN; TACROLIMUS; TOYOCAMYCIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL CELL CULTURE; FUNGUS CULTURE; FUNGUS GROWTH; HIGH THROUGHPUT NANO BIOFILM MICROARRAY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INFRARED SPECTROSCOPY; MICROARRAY ANALYSIS; MICROSCOPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

CANDIDA ALBICANS;

EID: 84883380529     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00331-13     Document Type: Article

References (52)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. 1999. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29:239-244.
2. Pittet D, Li N, Woolson RF, Wenzel RP. 1997. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin. Infect. Dis. 24:1068-1078.
3. Wenzel RP, Edmond MB. 2001. The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis. 7:174-177.
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
5. Wenzel RP. 2004. The antibiotic pipeline-challenges, costs, and values. N. Engl. J. Med. 351:523-526.
6. Gan M, Tang Y, Shu Y, Wu H, Chen L. 2012. Massively parallel bacterial and yeast suspension culture on a chip. Small 8:863-867.
7. Luo X, Shen K, Luo C, Ji H, Ouyang Q, Chen Y. An automatic microturbidostat for bacterial culture at constant density. Biomed Microdevices 2010:499-503.
8. Weibel DB, DiLuzio WR, Whitesides GM. 2007. Microfabrication meets microbiology. Nat. Rev. Microbiol. 5:209-218.
9. Balagaddé FK, You L, Hansen CL, Arnold FH, Quake SR. 2005. Longterm monitoring of bacteria undergoing programmed population control in a microchemostat. Science 309:137-140.
10. Hong SH, Hedge M, Kim J, Wang X, Jayaraman A, Wood TK. 2012, Synthetic quorum-sensing circuit to control consortial biofilm formation and dispersal in a microfluidic device. Nat. Commun. 3:613.
11. Keymer JE, Galajda P, Muldoon C, Park S, Austin RH. 2006. Bacterial metapopulations in nanofabricated landscapes. Proc. Natl. Acad. Sci. U. S. A. 103:17290-17295.
12. Mao H, Cremer PS, Manson MD. 2003. A sensitive, versatile microfluidic assay for bacterial chemotaxis. Proc. Natl. Acad. Sci. U. S. A. 100: 5449-5454.
13. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT. 2003. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U. S. A. 100:7977-7982.
14. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625.
15. Zhang L, Yan K, Zhang Y, Huang R, Bian J, Zheng C, Sun H, Chen Z, Sun N, An R, Min F, Zhao W, Zhuo Y, You J, Song Y, Yu Z, Liu Z, Yang K, Gao H, Dai H, Zhang X, Wang J, Fu C, Pei G, Liu J, Zhang S, Goodfellow M, Jiang Y, Kuai J, Zhou G, Chen X. 2007. Highthroughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl. Acad. Sci. U. S. A. 104:4606-4611.
16. LaFleur MD, Lucumi E, Napper AD, Diamond SL, Lewis K. 2011. Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms. J. Antimicrob. Chemother. 66:820-826.
17. Eun YJ, Weibel DB. 2009. Fabrication of microbial biofilm arrays by geometric control of cell adhesion. Langmuir 25:4643-4654.
18. Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. 2011. Development of a high-throughput Candida albicans biofilm Chip. PLoS ONE 6:e19036. doi: 10.1371/journal.pone.0019036.
19. Al-Sabagh AM, Noor El-Din MR, Morsi RE, Elsabee MZ. 2009. Styrenemaleic anhydride copolymer esters as flow improvers of waxy crude oil. J. Petrol. Sci. Eng. 65:139-146.
20. Kyeremateng SO, Amado E, Kressler J. 2007. Synthesis and characterization of random copolymers of (2,2-dimethyl-1,3-dioxolan-4-yl)methyl methacrylate and 2,3-dihydroxypropyl methacrylate. Eur. Polym. J. 43: 3380-3391.
21. Ivanova EP, Pham DK, Brack N, Pigram P, Nicolau DV. 2004. Poly(Llysine)-mediated immobilisation of oligonucleotides on carboxy-rich polymer surfaces. Biosens. Bioelectron. 19:1363-1370.
22. Chen Y, Bloemen V, Impens S, Moesen M, Luyten FP, Schrooten J. 2011. Characterization and optimization of cell seeding in scaffolds by factorial design: quality by design approach for skeletal tissue engineering. Tissue Eng. Part C Methods 17:1211-1221.
23. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183: 5385-5394.
24. Dong J, Mandenius CF, Lübberstedt M, Urbaniak T, Nüssler AK, Knobeloch D, Gerlach JC, Zeilinger K. 2008. Evaluation and optimization of hepatocyte culture media factors by design of experiments (DoE) methodology. Cytotechnology 57:251-261.
25. Sanglard D, Odds FC. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
26. Yeater KM, Chandra J, Cheng G, Mukherjee PK, Zhao X, Rodriguez-Zas SL, Kwast KE, Ghannoum MA, Hoyer LL. 2007. Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology 153:2373-2385.
27. Blankenship JR, Mitchell AP. 2006. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9:588-594.
28. Jabra-Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg. Infect. Dis. 10:14-19.
29. Kuhn DM, Ghannoum MA. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.
30. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35: 340-355.
31. Ramage G, Martínez JP, López-Ribot JL. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6:979-986.
32. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
33. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46: 3591-3596.
34. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71: 4333-4340.
35. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
36. Steinbach WJ, Reedy JL, Cramer RA, Perfect JR, Heitman J. 2007. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 5:418-430.
37. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7:e1002257. doi: 10.1371/ journal.ppat.1002257.
38. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P. 2000. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. 44:2932-2938.
39. Reedy JL, Husain S, Ison M, Pruett TL, Singh N, Heitman J. 2006. Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients. Antimicrob. Agents Chemother. 50:1573-1577.
40. Uppuluri P, Nett J, Heitman J, Andes D. 2008. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother. 52:1127-1132.
41. Okoli I, Coleman JJ, Tampakakis E, Tempakakis E, An WF, Holson E, Wagner F, Conery AL, Larkins-Ford J, Wu G, Stern A, Ausubel FM, Mylonakis E. 2009. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One 4:e7025. doi: 10.1371/journal.pone.0007025.
42. De Lucca AJ, Walsh TJ. 1999. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob. Agents Chemother. 43:1-11.
43. Opletalová V, Kalinowski DS, Vejsová M, Kunes J, Pour M, Jampílek J, Buchta V, Richardson DR. 2008. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity. Chem. Res. Toxicol. 21: 1878-1889.
44. Park HY, Kim MK, Moon SI, Cho YH, Lee CH. 2006. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclindependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci. 97:430-436.
45. Long MC, Parker WB. 2006. Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. I. Modifications to the adenine moiety. Biochem. Pharmacol. 71:1671-1682.
46. Kiburu IN, LaRonde-LeBlanc N. 2012. Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity. PLoS One 7:e37371. doi: 10.1371/ journal.pone.0037371.
47. Teal TK, Lies DP, Wold BJ, Newman DK. 2006. Spatiometabolic stratification of Shewanella oneidensis biofilms. Appl. Environ. Microbiol. 72: 7324-7330.
48. Renye JA, Piggot PJ, Daneo-Moore L, Buttaro BA. 2004. Persistence of Streptococcus mutans in stationary-phase batch cultures and biofilms. Appl. Environ. Microbiol. 70:6181-6187.
49. Uppuluri P, Srinivasan A, Ramasubramanian A, Lopez-Ribot JL. 2011. Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob. Agents Chemother. 55:3591-3593.
50. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. 2012. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 55:80-85.
51. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez-Ribot JL, Oliveira R. 2010. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 169:323-331.
52. Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. 2012. Candida albicans biofilm Chip (CaBChip) for high-throughput antifungal drug screening. J. Vis. Exp. 65:e3845.